Cell Therapy Safety & Translational Immunology: Novartis and Bristol Myers Squibb Pause Autoimmune CAR-T Trials Following Three Fatal IEC-HS Cases – Scrutinizing Hyper-Proliferation Risks in Rapid-Manufacturing Platforms

Key Development

In early September 2026, biopharmaceutical leaders Novartis AG (SIX: NOVN / NYSE: NVS) and Bristol Myers Squibb (NYSE: BMY) announced coordinated clinical interruptions across their respective autologous chimeric antigen receptor T-cell (CAR-T) programs in autoimmune indications, driven by severe hyper-inflammatory safety signals:

Divergent Operational Responses & Regulatory Holds:

• Novartis Program-Wide Halt (8 Trials Suspended Following 3 Fatalities): Effective August 24, 2026, Novartis instituted comprehensive clinical holds spanning eight clinical trials evaluating its next-generation CAR-T candidate rap-cel across immunology and neuroscience (including systemic lupus erythematosus, lupus nephritis, systemic sclerosis, idiopathic inflammatory myopathies, ANCA-associated vasculitis, rheumatoid arthritis, Sjögren’s disease, generalized myasthenia gravis, and multiple sclerosis). The decision followed the emergence of three cases of immune effector cell-associated hemophagocytic syndrome (IEC-HS) resulting in fatal patient outcomes. Oncology trials evaluating rap-cel remain active and unaffected.

• Bristol Myers Squibb Voluntary Enrollment Pause: BMS instituted a voluntary pause on new patient enrollment across its zola-cel (zolacabtagene autoleucel) autoimmune studies “out of an abundance of caution” to evaluate clinical safety datasets after detecting transient, reversible inflammatory events during routine safety surveillance. The company had disclosed one prior case of non-fatal IEC-HS in its Phase 1 trial in February, reaffirming ongoing confidence in zola-cel’s treatment-free remission profiles in systemic lupus.

• The Rapid Manufacturing Hypothesis: Both rap-cel (utilizing Novartis’ T-Charge platform) and zola-cel (BMS’ Nex-T platform) employ abbreviated ex vivo culture cycles (reducing manufacturing turnaround from weeks to 24–48 hours). Biotechnology analysts at William Blair highlighted that while rapid manufacturing preserves T-cell stemness and stem-cell memory phenotypes (Tscm), it may unleash explosive, uncontrolled in vivo cellular expansion within autoimmune microenvironments, triggering lethal macrophage hyper-activation and systemic toxicities.

Why It Matters

• Elevating Safety Thresholds for “Immune Reset” Paradigms: Transferring CAR-T technology from refractory hematological malignancies to chronic autoimmune disorders represents an important therapeutic horizon aimed at eradicating memory B-cell clones to achieve drug-free remissions. However, unlike late-stage oncology, non-malignant populations demand stringent safety-to-benefit ratios. Three treatment-related fatalities introduce regulatory caution that could recalibrate US FDA and EMA benefit-risk assessments.

• IEC-HS as an Under-Recognized Critical Complication: While cytokine release syndrome (CRS) and neurotoxicity (ICANS) are routinely managed with tocilizumab and high-dose dexamethasone, IEC-HS (a severe manifestation of macrophage activation syndrome / hemophagocytic lymphohistiocytosis) is marked by profound hyperferritinemia, progressive cytopenias, coagulopathy, and fulminant multi-organ failure, carrying high clinical mortality rates.

• Broader Industry Re-Alignment Across Cell Therapy Biotechs: The dual safety pause reverberated across the public markets, causing valuation volatility for competing clinical-stage developers including Kyverna Therapeutics, Cabaletta Bio, CRISPR Therapeutics, Allogene, and Autolus. The market is actively bifurcating developers utilizing rapid-manufacturing protocols against those employing conventional extended-culture or off-the-shelf allogeneic platforms.

Healthcare Insight Analysis

From the perspective of Healthcare Insight, the clinical holds initiated by Novartis and BMS illustrate the Autoimmune CAR-T Safety Reckoning & Manufacturing Trade-offs.

The safety developments highlight three primary translational science themes:

1. The In Vivo Expansion Paradox: Compressing ex vivo processing prevents T-cell exhaustion, yielding highly proliferative, stem-like cellular products. However, in an autoimmune host characterized by baseline systemic inflammatory priming, infusing hyper-potent cellular engines risks unchecked target engagement, triggering self-amplifying macrophage hyper-activation cascades.

2. Re-Evaluating Dosing and Conditioning Regimens: Dosing algorithms adapted directly from hematologic oncology may prove excessively toxic for non-malignant indications. Regulators will likely enforce strict dose-de-escalation strategies, milder lymphodepleting conditioning (attenuating fludarabine/cyclophosphamide protocols), or the integration of molecular suicide switches (such as inducible caspase-9) to abort runaway cell expansion.

3. Competitive Realignment Favoring Conventional CAR-Ts & T-Cell Engagers: This clinical hold grants a strategic window to biotechs utilizing traditional, controlled-expansion manufacturing processes (e.g., Cabaletta’s CABA-201, Kyverna’s KYV-101). Furthermore, it elevates the commercial positioning of off-the-shelf T-cell engaging bispecific antibodies (TCEs), which offer titratable, interruptible dosing profiles without requiring irreversible cellular infusions.

Market Implications

1. Extended Regulatory Review Windows & Commercial Delays: Novartis and BMS face multi-quarter clinical delays while conducting comprehensive cross-program safety audits and negotiating protocol amendments with the FDA, pushing potential biologics license application (BLA) filings past 2027–2028.

2. Mandatory Implementation of IEC-HS Monitoring Protocols: The US FDA and global regulators are expected to require standardized screening for macrophage activation biomarkers (serum ferritin, soluble CD25/IL-2R, triglycerides) and proactive pre-emptive intervention protocols utilizing IL-1 inhibitors (anakinra) or JAK inhibitors.

3. Heightened Due Diligence on Cell Therapy M&A: Strategic licensing deals and venture financings in autoimmune cell therapy will focus intensively on manufacturing kinetics, memory phenotype ratios, and reversible safety switches.

Comparative Strategic Matrix: Autoimmune CAR-T Clinical Pauses

Source: https://www.pharmexec.com/view/novartis-bristol-myers-pause-autoimmune-cart-trials-safety-concerns